ECSP014130A - Compuestos heterociclicos como ligandos de los receptores gaba. - Google Patents
Compuestos heterociclicos como ligandos de los receptores gaba.Info
- Publication number
- ECSP014130A ECSP014130A EC2001004130A ECSP014130A ECSP014130A EC SP014130 A ECSP014130 A EC SP014130A EC 2001004130 A EC2001004130 A EC 2001004130A EC SP014130 A ECSP014130 A EC SP014130A EC SP014130 A ECSP014130 A EC SP014130A
- Authority
- EC
- Ecuador
- Prior art keywords
- agonists
- ligandos
- gaba
- receivers
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Pyridine Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Lo que se divulga en el presente son compuestos heterocíclicos de la fórmula. Y sales farmacéuticas aceptables de la misma cuya característica es que las variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n y m se definen en el presente. Estos compuestos son agonistas, antagonistas o agonistas invertidos?? Altamente selectivos para los receptores cerebrales GABAA O pro-fármacos de agonistas, antagonistas o agonistas invertidos para los receptores cerebrales GABAA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22366900P | 2000-08-07 | 2000-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP014130A true ECSP014130A (es) | 2002-03-25 |
Family
ID=22837525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2001004130A ECSP014130A (es) | 2000-08-07 | 2001-08-07 | Compuestos heterociclicos como ligandos de los receptores gaba. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6653471B2 (es) |
| EP (1) | EP1325006A2 (es) |
| JP (1) | JP2004505942A (es) |
| KR (1) | KR20030036678A (es) |
| CN (1) | CN1468241A (es) |
| AU (1) | AU2001285401A1 (es) |
| BR (1) | BR0113120A (es) |
| CA (1) | CA2420967A1 (es) |
| CO (1) | CO5310576A1 (es) |
| EC (1) | ECSP014130A (es) |
| HN (1) | HN2002000193A (es) |
| IL (1) | IL154310A0 (es) |
| MX (1) | MXPA03001186A (es) |
| PA (1) | PA8524601A1 (es) |
| PE (1) | PE20020275A1 (es) |
| PY (1) | PY0119496A (es) |
| TN (1) | TNSN01122A1 (es) |
| UY (1) | UY26874A1 (es) |
| WO (1) | WO2002012442A2 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500253A (ja) * | 2001-02-23 | 2005-01-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物 |
| AU2003212979A1 (en) * | 2002-02-07 | 2003-09-02 | Neurogen Corporation | Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
| FR2857363B1 (fr) * | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
| MX2007007919A (es) * | 2004-12-31 | 2008-01-22 | Reddy Us Therapeutics Inc | Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| US8583926B1 (en) | 2005-09-19 | 2013-11-12 | Jpmorgan Chase Bank, N.A. | System and method for anti-phishing authentication |
| WO2007053352A2 (en) * | 2005-10-28 | 2007-05-10 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| US20070099911A1 (en) * | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| US20090075968A1 (en) * | 2005-12-29 | 2009-03-19 | Junichi Sakaki | CETP inhibitors |
| AU2007247385B2 (en) | 2006-05-10 | 2011-07-14 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
| CN101443324A (zh) * | 2006-05-11 | 2009-05-27 | 诺瓦提斯公司 | 作为cetp抑制剂的苄胺衍生物 |
| AU2007321283A1 (en) * | 2006-11-15 | 2008-05-22 | Novartis Ag | Heterocyclic derivatives as CETP inhibitors |
| EP2190850A4 (en) * | 2007-07-03 | 2011-03-09 | Univ British Columbia | DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES |
| AU2009257602B2 (en) * | 2008-06-10 | 2015-10-08 | Abbvie Inc. | Novel tricyclic compounds |
| KR101354416B1 (ko) * | 2009-05-07 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체 |
| EP4782062A2 (en) | 2009-12-01 | 2026-07-29 | AbbVie Inc. | Novel tricyclic compounds |
| JP2013512282A (ja) | 2009-12-01 | 2013-04-11 | アボット・ラボラトリーズ | 新規三環式化合物 |
| CN102712640A (zh) * | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| BR112013033777A2 (pt) * | 2011-03-15 | 2016-09-13 | Abbvie Inc | moduladores de receptor de hormônio nuclear |
| AU2012321345B2 (en) | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| TW201422590A (zh) | 2012-09-07 | 2014-06-16 | Abbvie Inc | 雜環核激素受體調節劑 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| KR101612179B1 (ko) * | 2013-04-19 | 2016-04-12 | 영남대학교 산학협력단 | 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 |
| WO2015125858A1 (ja) * | 2014-02-24 | 2015-08-27 | 日本曹達株式会社 | ヘテロアリール化合物およびその用途 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11891377B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206415A (en) | 1991-12-20 | 1993-04-27 | Washington University | Tricyclic steroid analogs |
| US5344626A (en) * | 1992-06-26 | 1994-09-06 | Minnesota Mining And Manufacturing Company | Dual impregnated activated carbon |
| US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
| GB9708945D0 (en) | 1997-05-01 | 1997-06-25 | Merck Sharp & Dohme | Therapeutic agents |
| WO1998050385A1 (en) * | 1997-05-08 | 1998-11-12 | Merck Sharp & Dohme Limited | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS |
| GB9713707D0 (en) | 1997-06-27 | 1997-09-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO1999029319A2 (en) * | 1997-12-09 | 1999-06-17 | Neurosearch A/S | Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds |
| AU2793199A (en) * | 1998-02-26 | 1999-09-15 | Neurogen Corporation | 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors |
| US6103903A (en) * | 1998-02-26 | 2000-08-15 | Neurogen Corporation | 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands |
-
2001
- 2001-08-06 AU AU2001285401A patent/AU2001285401A1/en not_active Abandoned
- 2001-08-06 US US09/924,174 patent/US6653471B2/en not_active Expired - Fee Related
- 2001-08-06 IL IL15431001A patent/IL154310A0/xx unknown
- 2001-08-06 BR BR0113120-6A patent/BR0113120A/pt not_active IP Right Cessation
- 2001-08-06 PY PY200100119496A patent/PY0119496A/es unknown
- 2001-08-06 MX MXPA03001186A patent/MXPA03001186A/es active IP Right Grant
- 2001-08-06 JP JP2002517733A patent/JP2004505942A/ja active Pending
- 2001-08-06 KR KR10-2003-7001844A patent/KR20030036678A/ko not_active Withdrawn
- 2001-08-06 EP EP01964561A patent/EP1325006A2/en not_active Withdrawn
- 2001-08-06 CN CNA018169902A patent/CN1468241A/zh active Pending
- 2001-08-06 CA CA002420967A patent/CA2420967A1/en not_active Abandoned
- 2001-08-06 WO PCT/US2001/041572 patent/WO2002012442A2/en not_active Ceased
- 2001-08-07 PE PE2001000785A patent/PE20020275A1/es not_active Application Discontinuation
- 2001-08-07 PA PA20018524601A patent/PA8524601A1/es unknown
- 2001-08-07 UY UY26874A patent/UY26874A1/es not_active Application Discontinuation
- 2001-08-07 TN TNTNSN01122A patent/TNSN01122A1/fr unknown
- 2001-08-07 EC EC2001004130A patent/ECSP014130A/es unknown
- 2001-08-08 CO CO01063854A patent/CO5310576A1/es not_active Application Discontinuation
-
2002
- 2002-07-24 HN HN2002000193A patent/HN2002000193A/es unknown
-
2003
- 2003-09-23 US US10/670,077 patent/US6949562B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6949562B2 (en) | 2005-09-27 |
| BR0113120A (pt) | 2004-06-22 |
| WO2002012442A2 (en) | 2002-02-14 |
| KR20030036678A (ko) | 2003-05-09 |
| TNSN01122A1 (fr) | 2005-11-10 |
| UY26874A1 (es) | 2002-03-22 |
| CO5310576A1 (es) | 2003-08-29 |
| MXPA03001186A (es) | 2004-04-20 |
| PY0119496A (es) | 2003-11-03 |
| CA2420967A1 (en) | 2002-02-14 |
| HN2002000193A (es) | 2002-11-05 |
| CN1468241A (zh) | 2004-01-14 |
| US6653471B2 (en) | 2003-11-25 |
| US20030105081A1 (en) | 2003-06-05 |
| AU2001285401A1 (en) | 2002-02-18 |
| PE20020275A1 (es) | 2002-04-09 |
| PA8524601A1 (es) | 2003-09-05 |
| EP1325006A2 (en) | 2003-07-09 |
| IL154310A0 (en) | 2003-09-17 |
| US20040110778A1 (en) | 2004-06-10 |
| WO2002012442A3 (en) | 2003-05-01 |
| JP2004505942A (ja) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26874A1 (es) | Compuestos heterocíclicos como ligandos de los receptores gaba | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| ES2184070T3 (es) | Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina. | |
| PA8657501A1 (es) | Derivados de piperida y su uso como agentes antiinflamatorios | |
| HN1999000149A (es) | Derivados de 4,4-biarilpiperidina | |
| ECSP066447A (es) | Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas | |
| CR7812A (es) | Compuestos de purina y usos de los mismos como ligandos de receptor de cannabinoides | |
| CL2004000861A1 (es) | Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp | |
| AR003937A1 (es) | Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene. | |
| ECSP066643A (es) | PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 | |
| UY27918A1 (es) | Derivados de benzodioxol | |
| ECSP034830A (es) | Derivados sustituidos de la ciclohexano-1,4- diamina | |
| PA8577001A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
| CO2022003062A2 (es) | Compuestos heterocíclicos | |
| CR8387A (es) | Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos | |
| UY26729A1 (es) | Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos | |
| UY27851A1 (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| CR8312A (es) | Nuevas sulfonamidas como agentes fitosanitarios | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| PA8589801A1 (es) | Aminoalcoxiindoles | |
| PA8587501A1 (es) | Benzoxazinonas sustituidas y usos de las mismas | |
| CR8092A (es) | Pirazolopirimidinas sustituidas, procedimientos para su obtencion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen | |
| PA8486701A1 (es) | Antagonistas de 5ht1 para terapia antidepresiva |